NEWRON PHARMACEUTICALS COMPLETES EUR30 MILLION SERIES B FINANCING

Newron Pharmaceuticals SpA, a late-stage discovery and development company focusing on novel CNS therapies, today announced the completion of a EUR30 million Series B round with the addition of TVM in a second closing of EUR7 million.The transaction represents the first investment by the recently closed TVM LSV VI fund, managed by TVM GmbH, Germany, one of the most experienced Venture Capital firms in the life science industry.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-05-2005/0004159976&EDATE=)